Clinical Trials
4
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Study Evaluating the Ketogenic Diet in Patients with Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Translational Drug Development
- Target Recruit Count
- 32
- Registration Number
- NCT04631445
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Nuvance Health-Danbury Hospital, Danbury,, Connecticut, United States
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Translational Drug Development
- Target Recruit Count
- 25
- Registration Number
- NCT01919749
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer
- Conditions
- Previously Treated Metastatic Pancreatic Cancer
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Translational Drug Development
- Target Recruit Count
- 35
- Registration Number
- NCT01196247
- Locations
- 🇺🇸
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Approved therapy will be assigned based on molecular profile and RPMA results
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Translational Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT01074814
- Locations
- 🇺🇸
Tgen Clinical Research Services, Scottsdale, Arizona, United States
🇺🇸Fairfax North Virginia Hematology Oncology, Fairfax, Virginia, United States
🇺🇸Evergreen Hematology and Oncology, Spokane, Washington, United States
News
Provectus Biopharmaceuticals Launches Preclinical Study of Oral PV-10 for Bladder Cancer Treatment
Provectus Biopharmaceuticals has initiated a preclinical study evaluating oral PV-10 in an orthotopic bladder cancer model, with results expected in Q1 2026.